Fonkem_edited.jpg

  Ekokobe Fonkem, DO

A retrospective analysis of meningioma in Central Texas

Ekokobe FonkemJad A. Dandashi, Edana Stroberg, 

David Garrett,Frank S. Harris,Ibrahim M.

El Nihuma, James Cooper,

Samantha Dayawansa, sdayawansa@sw.org

Jason H. Huang

Corresponding Author Samantha Dayawansa

sdayawansa@sw.org

Journal of Epidemiology and Global Health Volume 6, Issue 2,  June 2016, Pages 87 - 93

Received 30 March 2015, Revised 6 January 2016,  Accepted 13 January 2016,

Available Online 3 February 2016.

DOI: https://doi.org/10.1016/j.jegh.2016.01.001 

(Click LINK or HERE)

EPID-03 - THE MINORITY ADVANTAGE-DISPARITIES BRAIN TUMOR SURVIVAL IN TEXAS STATE 1995-2013

Ambe, Solomon and Olanipekun, Olalekan and

Fonkem, Ekokobe
Neuro-Oncology, Volume 20, Issue suppl_6,

01 November 2018,

Page vi80, 

Published: 05 November 2018

https://doi.org/10.1093/neuonc/noy148.330   

(Click LINK or HERE)

 

 

   Current Meningioma Brain Tumor Medical Practitioners, Research Pioneers                                                        and                                                                 Supporting Partners of Meningioma Brain Tumor Network, Inc

The focus on the continuous development of treatment approaches and applied/active research specifically for meningioma brain tumor patients, survivors, and the myriad of supports needed for appropriate care, can be credited to these two "giants" in neurology / neuro-oncology. 

Meningioma Brain Tumor Network, Inc is indeed fortunate to have direct access to Dr. Fonkem and Researcher Najafabadi and therefore, have profiled some of their most current meningioma brain tumor research publications, as well as a brief overview of in-process treatment initiatives, which established the foundation and pillars for services we provide.

MBTN, Inc's Co-Labs (Collaborative Laboratories) Model is currently being field-tested by Dr. Fonkem at Barrow Neurological Institute's Meningioma Day Clinic (a monthly clinic designed specifically to provide multidisciplinary services for meningioma patients/survivors).            

Additionally, MBTN, Inc has joined forces with Dr. Fonkem in the beginnings of the design and creation of the Center for Meningioma Care, where the inherent vision of the said center, is to establish a nationally, the first of it kind, multifaceted interprofessional care/multidisciplinary healthcare center, that will provide a cadre of collaborative services to meningioma patients/survivors pre and post-operatively, eliminate the gaps and make needed improvements in research on meningioma brain tumors, while offering training (multidisciplinary medical fellowships and education) and professional development for other healthcare providers.

handshake-2009195_1920.png

                                             Co-Labs                                                     

MBTN's Collaborative Laboratories (Co-Labs) are designed and constructed to empower patients, caregivers, and advocates by developing a consortium of healthcare professionals and a cadre of business partners (e.g. insurance companies, foundations, women's health advocates, and others). The 

Co-Labs use a continuum of care model to provide ongoing consultation, and accurate information via the following: Co-Labs service identifiers, resource hotline web links, online portals, podcasts' discussions, and social media posts, which will ensure that services are provided to meningioma brain tumor patients that are equitable and progressive relative to quality women's healthcare. Each of these approaches is imperative for survivors to access MBTN's services using remote modalities due to numerous health and safety protocols under COVID-19 and future pandemic crises. 

                           

A long-range goal of MBTN, Inc, is to join in the crusade to extinguish healthcare disparities associated with minority women afflicted with meningioma brain tumors, by creating a formidable platform for exploring better treatment options (short and long term) and seeking direct funding for the establishment of national and international Centers for Meningioma Care, where conducting specialized treatment options and applied/action research on non-cancerous brain tumors such as meningiomas.  The aforementioned statements are the exclusive focus for this brain disease which continues to remain an enigma within the vast realms of medicine, healthcare, and health and human services fields.

Amir.jpg

   Amir H. Zamanipoor Najafabadi, MD

Visual outcomes endorse surgery of patients with spheno-orbital meningioma with minimal visual impairment or hyperostosis

Amir H. Zamanipoor Najafabadi 1 & Stijn W. Genders 2,3Wouter R. van Furth 1 : 5                       

Acta Neurochirurgica (Received: 05 July 2020/Accepted: 24 August 2020 

Published: 04 September 2020

DOI: https://doi.org/10.1007/s00701-020-04554-9 

(Click LINK or HERE)

Surgery as a safe and effective treatment option for    spheno‐orbital meningioma: a systematic review and  meta‐analysis of surgical techniques and outcomes

Fleur L. Fisher; Amir H. Zamanipoor Najafabadi; Jan W. SchoonesStijn W. GendersWouter R. van Furth

Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation    

First published: 29 June 2020 

 https://doi.org/10.1111/aos.14517                              (Click LINK or HERE)

Unmet needs and recommendations to improve meningioma care through patient, partner, and health care provider input: A Mixed-Method Study 

Amir H Zamanipoor NajafabadiJohannes P M van de MortelDaniel J LobattoDieta R BrandsmaWilco C PeulNienke BiermaszMartin J B TaphoornLinda DirvenWouter R van Furth

Neuro-Oncology Practice, Volume 7, Issue 2, April 2020, Pages 239–248,   

Published:  02 November 2019

https://doi.org/10.1093/nop/npz055 

(Click LINK or HERE)